Pancreatic cancer remains the fourth leading cause of cancer-related death in the USA with a 5-year survival rate of 5 %. The effects of epidermal growth factor receptor and vascular endothelial growth factor A blockade with chemotherapy on pancreatic tumor growth were examined. Mice bearing human PANC-1 cell xenografts were divided into three groups: T-CR (gemcitabine, cisplatin, and 5-fluorouracil), T-TR (cetuximab, bevacizumab, gemcitabine, cisplatin, and 5-fluorouracil), and vehicle control (T). The therapies were administered via intraperitoneal injections every 4 days for seven cycles from 7 weeks after cancer cell implantation. Mice treated with T-TR had significant reductions in tumor weight as compared to the control group (p <0.05). Although mice in the T-CR group experienced a significant reduction in body weight gain, serum albumin, and gastrocnemius muscle mass (p <0.05), no such reductions were observed in the T-TR group. Mice treated with T-TR had slightly increased CD11c+ DC and CD49b+ NK cell levels in the spleen (p <0.05) and significantly lower tumor VEGF expression (p <0.05). Tumor carcinoembryonic antigen expression was significantly reduced in both treatment groups (p <0.05). Thus, addition of bevacizumab and cetuximab to gemcitabine, cisplatin, and fluorouracil may represent an effective treatment option for pancreatic cancer that warrants further study.
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Tai, C. J., Wang, H., Wang, C. K., Tai, C. J., Huang, M. T., Wu, C. H., Chen, R. J., Kuo, L. J., Wei, P. L., Chang, Y. J., Chang, C. C., Chiou, H. Y., & Wu, C. J. (2017). Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts. Clinical and Experimental Medicine, 17(2), 141-150. https://doi.org/10.1007/s10238-016-0409-2